TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Purchased by Avaii Wealth Management LLC

Avaii Wealth Management LLC raised its stake in TG Therapeutics, Inc. (NASDAQ:TGTX) by 4.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 30,393 shares of the biopharmaceutical company’s stock after buying an additional 1,409 shares during the quarter. Avaii Wealth Management LLC’s holdings in TG Therapeutics were worth $915,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of TGTX. State Street Corp raised its holdings in shares of TG Therapeutics by 35.8% in the 3rd quarter. State Street Corp now owns 9,094,158 shares of the biopharmaceutical company’s stock valued at $212,712,000 after buying an additional 2,398,015 shares during the period. Charles Schwab Investment Management Inc. lifted its position in shares of TG Therapeutics by 0.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,184,609 shares of the biopharmaceutical company’s stock worth $27,708,000 after purchasing an additional 7,939 shares in the last quarter. Principal Financial Group Inc. boosted its stake in shares of TG Therapeutics by 1,549.4% in the third quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company’s stock valued at $18,061,000 after purchasing an additional 725,371 shares during the period. JPMorgan Chase & Co. grew its holdings in shares of TG Therapeutics by 60.0% in the third quarter. JPMorgan Chase & Co. now owns 720,798 shares of the biopharmaceutical company’s stock valued at $16,859,000 after purchasing an additional 270,286 shares in the last quarter. Finally, Point72 Asset Management L.P. purchased a new stake in TG Therapeutics during the 2nd quarter worth approximately $10,423,000. Hedge funds and other institutional investors own 58.58% of the company’s stock.

Insiders Place Their Bets

In related news, Director Sagar Lonial sold 5,000 shares of TG Therapeutics stock in a transaction on Monday, November 11th. The stock was sold at an average price of $30.44, for a total transaction of $152,200.00. Following the completion of the transaction, the director now directly owns 100,195 shares of the company’s stock, valued at approximately $3,049,935.80. The trade was a 4.75 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO Sean A. Power sold 11,337 shares of the stock in a transaction dated Friday, January 3rd. The shares were sold at an average price of $30.29, for a total transaction of $343,397.73. Following the completion of the sale, the chief financial officer now directly owns 670,632 shares in the company, valued at approximately $20,313,443.28. The trade was a 1.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 26,358 shares of company stock worth $781,497. 10.50% of the stock is owned by corporate insiders.

TG Therapeutics Stock Performance

NASDAQ TGTX opened at $31.26 on Friday. The firm has a market cap of $4.87 billion, a P/E ratio of -312.57 and a beta of 2.24. TG Therapeutics, Inc. has a 52-week low of $12.84 and a 52-week high of $36.84. The business’s 50-day moving average price is $31.57 and its 200 day moving average price is $26.16. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.03 by ($0.01). The company had revenue of $83.90 million for the quarter, compared to analysts’ expectations of $81.68 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. TG Therapeutics’s revenue for the quarter was down 49.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.73 EPS. On average, equities research analysts expect that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have commented on TGTX. HC Wainwright restated a “buy” rating and issued a $55.00 price target on shares of TG Therapeutics in a research note on Wednesday, January 15th. StockNews.com upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, January 7th. The Goldman Sachs Group lifted their price objective on TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. TD Cowen initiated coverage on shares of TG Therapeutics in a research note on Tuesday, October 29th. They set a “buy” rating and a $50.00 target price on the stock. Finally, JPMorgan Chase & Co. lifted their price target on shares of TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a research note on Monday, November 25th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, TG Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $40.67.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.